Impact of interventions by a community pharmacist on care burden for people with dementia: development and randomized feasibility trial of an intervention protocol

Yoko Nanaumi, Atsushi Yoshitani, Mitsuko Onda, Yoko Nanaumi, Atsushi Yoshitani, Mitsuko Onda

Abstract

Background: Traditionally, the role of pharmacists has been to manage and monitor pharmacotherapy for patients with dementia. However, additional intervention by community pharmacists to collect and share patient information with other professionals may help reduce the care burden among caregivers. The aims of this study were to examine (1) the feasibility of a designed community pharmacist working procedure in dementia care and (2) the expected impact of pharmacist intervention on care burden.

Methods: This was a randomized, open-label, parallel-group feasibility study, involving eight Nara City pharmaceutical association member pharmacies that provided consent to participate. These pharmacies were assigned to an intervention group or a control group at a 1:1 ratio. The subjects were patients with dementia and their primary caregivers that visited the participating pharmacies and provided consent to participate. Pharmacists in the intervention group actively collected information from the patients' family physicians and care managers and intervened to address medication-related problems, while those in the control group only performed their normal duties. The primary endpoint was a change in the caregiver's score on the Japanese version of Zarit Caregiver Burden interview (J-ZBI) from the baseline to after 5 months of follow-up. The changes in mean J-ZBI scores from the beginning to the end of the study period of the two groups were compared.

Results: Obtaining consent from caregivers was certainly difficult, but possible. Pharmacists managed to fill out the survey form while practising pharmaceutical care. Totally, nine patients and nine caregivers in the intervention group and nine patients and eight caregivers in the control group completed the study. The changes in J-ZBI scores could be calculated for seven cases in the intervention group and five cases in the control group. The J-ZBI scores were found to decrease by 1.0 in the intervention group and increase by 3.0 in the control group.

Conclusions: The protocol presented was considered feasible, but, the intervention process needs to be simplified in order to conduct a large study. Also, improvements are needed in the various survey forms and in the explanatory documents for caregivers. Although the sample size was small, the effect sizes suggested that community pharmacist interventions for patient with dementia may reduce the care burden for caregivers.

Trial registration: UMIN000039949 (registration date: 1 April 2020, retrospectively registered).

Keywords: Caregiver burden; Community pharmacist; Dementia.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study protocol for the two groups
Fig. 2
Fig. 2
Consort flowchart of participant selection

References

    1. Alzheimer’s Disease International. World Alzheimer report 2019. . Accessed 29 Apr 2019.
    1. Cabinet Office Japan. Annual report on the ageing society [summary] FY 2019. . Accessed 29 Apr 2019.
    1. Cheng ST. Dementia caregiver burden: a research update and critical analysis. Curr Psychiatry Rep. 2017;19:64. doi: 10.1007/s11920-017-0818-2.
    1. Chiao CY, Wu HS, Hsiao CY. Caregiver burden for informal caregivers of patients with dementia: a systematic review. Int Nurs Rev. 2015;62:340–350. doi: 10.1111/inr.12194.
    1. World Health Organization . Towards a dementia plan: a WHO guide. 2018.
    1. Hughes TB, Black BS, Albert M, Gitlin L, Johnson D, Lyketsos C, et al. Correlates of objective and subjective measures of caregiver burden among dementia caregivers: influence of unmet patient and caregiver dementia-related care needs. Int Psychogeriatr. 2014;26:1875–1883. doi: 10.1017/S1041610214001240.
    1. Naganuma Y, Kihara S, Fujita Y, Yamaoka K, Takahashi K. The relation between social cohesion and the care burden of family healthcare providers. BioSci Trends. 2018;12:520–522. doi: 10.5582/bst.2018.01175.
    1. Gilliam CM, Steffen AM. The relationship between caregiving self-efficacy and depressive symptoms in dementia family caregivers. Aging Ment Health. 2006;10:79–86. doi: 10.1080/13607860500310658.
    1. Vaingankar JA, Chong SA, Abdin E, Picco L, Jeyagurunathan A, Zhang YJ, et al. Care participation and burden among informal caregivers of older adults with care needs and associations with dementia. Int Psychogeriatr. 2016;28:221–231. doi: 10.1017/S104161021500160X.
    1. Saeki A. The influence of family functions and family systems on primary caregiver burden caring for elderly people with dementia. Jpn Red Cross Kyushu Int Coll Nurs. 2006;5:55–62.
    1. Sӧrensen S, Pinquart M, Duberstein P. How effective are interventions with caregivers? An updated meta-analysis. Gerontologist. 2002;42:356–372. doi: 10.1093/geront/42.3.356.
    1. Nguyen M, Pachana NA, Beattie E, Fielding E, Ramis MA. Effectiveness of interventions to improve family-staff relationships in the care of people with dementia in residential aged care: a systematic review protocol. JBI Database System Rev Implement Rep. 2015;13:52–63. doi: 10.11124/jbisrir-2015-2415.
    1. Gallagher D, Ni Mhaolain A, Crosby L, Ryan D, Lacey L, Coen RF, et al. Self-efficacy for managing dementia may protect against burden and depression in Alzheimer’s caregivers. Aging Ment Health. 2011;15:663–670. doi: 10.1080/13607863.2011.562179.
    1. Department of Health . Prime Ministers challenge on dementia. 2020.
    1. Alzheimer Europe. Policy: national dementia strategies. . Accessed 9 July 2020.
    1. Government of Canada . A dementia strategy for Canada: together we aspire: in brief. 2019.
    1. Ministry of Health and Welfare . Japanese dementia strategy (new orange plan) 2017.
    1. Cotelo NV, Rodríguez NFA, Pérez JAF, Iglesias JCA, Lago MR. Burden and associated pathologies in family caregivers of Alzheimer’s disease patients in Spain. Pharm Pract. 2015;13:521. doi: 10.18549/pharmpract.2015.02.521.
    1. Goedken AM, Huang S, McDonough RP, Deninger MJ, Doucette WR. Medication-related problems identified through continuous medication monitoring. Pharmacy. 2018;6:86. doi: 10.3390/pharmacy6030086.
    1. While C, Duane F, Beanland C, Koch S. Medication management: the perspectives of people with dementia and family carers. Dementia. 2013;12:734–750. doi: 10.1177/1471301212444056.
    1. Marasco R, Heely JA, Gardner M. The pharmacist’s role in managing patients with Alzheimer’s disease. J Am Pharm Assoc. 2003;43:S20–S21. doi: 10.1331/154434503322612339.
    1. Nakamura K, Watanabe N, Ohkawa H, Ando M, Ogura Y, Funabiki S, et al. Effects on caregiver burden of a donepezil hydrochloride dosage increase to 10 mg/day in patients with Alzheimer’s disease. Patient Prefer Adherence. 2014;8:1223–1228. doi: 10.2147/PPA.S69750.
    1. Kröger E, Tatar O, Vedel I, Giguère AMC, Voyer P, Guillaumie L, et al. Improving medication adherence among community-dwelling seniors with cognitive impairment: a systematic review of interventions. Int J Clin Pharm. 2017;39:641–656. doi: 10.1007/s11096-017-0487-6.
    1. Hudani ZK, Rojas-Fernandez CH. A scoping review on medication adherence in older patients with cognitive impairment or dementia. Res Social Adm Pharm. 2016;12:815–829. doi: 10.1016/j.sapharm.2015.11.011.
    1. Maidment ID, Aston L, Hilton A, Iqbal N, Child A, Shaw R. Role of community pharmacists in the use of antipsychotics for behavioural and psychological symptoms of dementia (BPSD): a qualitative study. BMJ Open. 2016;6:e010278. doi: 10.1136/bmjopen-2015-010278.
    1. Nanaumi Y, Onda M, Tsubota K, Tanaka R, Mukai Y, Matoba S, et al. Effectiveness of pharmacists’ comprehensive assessment of medication profiles in dementia patients. Yakugaku Zasshi. 2015;135:1057–1067. doi: 10.1248/yakushi.15-00109.
    1. Novais T, Mouchoux C. Pharmaceutical care for patients and their caregivers in Alzheimer’s disease and related disorders: a review and new perspectives. Geriatr Psychol Neuropsychiatr Vieil. 2019;17:7–19. doi: 10.1684/pnv.2018.0767.
    1. Dann-Reed E, Poland F, Wright D. Systematic review to inform the development of a community pharmacy-based intervention for people affected by dementia. Int J Pharm Pract. 2020;28:233–245. doi: 10.1111/ijpp.12586.
    1. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239. doi: 10.1136/bmj.i5239.
    1. Arai Y, Kudo K, Hosokawa T, Washio M, Miura H, Hisamichi S. Reliability and validity of the Japanese version of the Zarit Caregiver Burden Interview. Psychiatry Clin Neurosci. 1997;51:281–287. doi: 10.1111/j.1440-1819.1997.tb03199.x.
    1. Ueno H, Yamazaki Y, Ishikawa H. Reliability and validity of medication adherence scale for patients with chronic disease in Japan. Jap J Health Educ Promot. 2014;22:13–29.
    1. Kubo T, Kaji M, Tsuji S, Asakura M, Higuchi K, Mukai E, et al. Improvement of method to estimate guidance by pharmacists and trial to obtain standard pharmaceutical management and guidance services program. Yakugaku Zasshi. 2001;121:221–232. doi: 10.1248/yakushi.121.221.
    1. Sullivan GM, Feinn R. Using effect size—or why the P value is not enough. J Grad Med Educ. 2012;4:279–282. doi: 10.4300/JGME-D-12-00156.1.
    1. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Erlbaum; 1998.
    1. Bernstein A, Merrilees J, Dulaney S, Harrison KL, Chiong W, Ong P, et al. Using care navigation to address caregiver burden in dementia: a qualitative case study analysis. Alzheimer’s Dement. 2020;6:e12010. doi: 10.1002/trc2.12010.
    1. Weissenborn M, Haefeli WE, Peters-Klimm F, Seidling HM. Interprofessional communication between community pharmacists and general practitioners: a qualitative study. Int J Clin Pharm. 2017;39:495–506. doi: 10.1007/s11096-017-0450-6.
    1. Sato S, Kazui H, Shimizu Y, Yoshida T, Yoshiyama K, Kanemoto H, et al. Usefulness of carer-held records to support informal caregivers of patients with dementia who live at home. Psychogeriatrics. 2018;18:166–174. doi: 10.1111/psyg.12304.
    1. Nanaumi Y, Onda M, Mukai Y, Tanaka R, Tubota K, Matoba S, et al. Factors related to medication adherence of cognitively impaired patients in community pharmacies. Pharmacol Pharm. 2012;3:368–380. doi: 10.4236/pp.2012.33050.
    1. Sakurai N. The moderating effects of positive appraisal on the burden of family caregivers of older people. Shinrigaku Kenkyu. 1999;70:203–210. doi: 10.4992/jjpsy.70.203.
    1. El-Saifi N, Moyle W, Jones C. Family caregivers’ perspectives on medication adherence challenges in older people with dementia: a qualitative study. Aging Ment Health. 2019;23:1333–1339. doi: 10.1080/13607863.2018.1496226.
    1. Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer’s disease under daily practice conditions. Int J Clin Pract. 2014;68:465–470. doi: 10.1111/ijcp.12374.
    1. Qiu D, Hu M, Yu Y, Tang B, Xio S. Acceptability of psychosocial interventions for dementia caregivers: a systematic review. BMC Psychiatry. 2019;19:23. doi: 10.1186/s12888-018-1976-4.
    1. Teahan Á, Lafferty A, McAuliffe E, Phelan A, O’Sullivan L, O’Shea D, et al. Psychosocial interventions for family carers of people with dementia: a systematic review and meta-analysis. J Aging Health. 2020;32:1198–1213. doi: 10.1177/0898264319899793.
    1. Kumamoto K, Arai Y. Validation of ‘personal strain’ and ‘role strain’: subscales of the short version of the Japanese version of the Zarit Burden Interview (J-ZBI_8) Psychiatry Clin Neurosci. 2004;58:606–610. doi: 10.1111/j.1440-1819.2004.01310.x.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren